Skip to main content

Catalyst Calendar

Tue, Sep 1, 2026

1 updates

4:05 PM

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

karyopharm.com

Mon, Aug 31, 2026

1 updates

7:30 AM

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

karyopharm.com

Thu, Aug 13, 2026

1 updates

7:30 AM

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

karyopharm.com

Mon, Aug 10, 2026

1 updates

7:30 AM

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

karyopharm.com

Mon, Aug 3, 2026

1 updates

4:05 PM

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

karyopharm.com

Thu, Jul 30, 2026

2 updates

4:06 PM

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

karyopharm.com

4:05 PM

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

Trial Results • Phase 3Topline results Thu, Jul 30, 2026karyopharm.com

Wed, Jul 1, 2026

1 updates

4:05 PM

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

karyopharm.com